價(jià)格 | ¥315 | ¥438 | ¥697 |
包裝 | 5mg | 10mg | 25mg |
最小起訂量 | 1mg |
發(fā)貨地 | 上海 |
更新日期 | 2024-09-29 |
中文名稱:鄰甲苯海明 | 英文名稱:Orphenadrine |
CAS:83-98-7 | 品牌: TargetMol |
產(chǎn)地: 美國(guó) | 保存條件: Shipping with blue ice. |
純度規(guī)格: 99.38% | 產(chǎn)品類別: 抑制劑 |
貨號(hào): T68599 |
名稱 | Orphenadrine |
描述 | Orphenadrine is a noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist that inhibits clonal HERG channels in a concentration-dependent manner, producing an IC of 0.85 μM in HEK cells.Orphenadrine is an antagonist of central and peripheral muscarinic receptors. Attenuation is blocked by mutations in pore residues Y652 or F656. Orphenadrine has antispasmodic, analgesic, and anticholinergic activity and protects against glutamatergic neurotoxicity in vitro and in vivo.Orphenadrine has inhibitory effects on sodium channels and can be used in the treatment of Parkinson's disease. |
體外活性 | Orphenadrine decreased CYP2B6 marker activity up to 45-57% in human liver microsomes and up to 80-97% in cell microsomes containing cDNA-expressed CYP2B6. Orphenadrine strongly decreased CYP2D6 marker activity by 80-90%. Orphenadrine also partially decreased the CYP1A2, CYP2A6, CYP3A4, and CYP2C19 marker activities.[4] |
體內(nèi)活性 | Orphenadrine (75 mg/kg/day; i.p.; for 3 days) was associated with a 2-fold induction of total hepatic P-450, a 5- and 2.4-fold induction of androstenedione 16 beta- and 6 beta-hydroxylase activity, respectively, and formation of an orphenadrine-P-450 MI complex. Western blots of orphenadrine-induced microsomes revealed a 20-fold increase in P-450 PB-B/D-immunoreactive protein.[2] |
存儲(chǔ)條件 | Shipping with blue ice. |
溶解度 | DMSO : 50 mg/mL (185.61 mM) |
關(guān)鍵字 | Orphenadrine |
相關(guān)產(chǎn)品 | Lidocaine hydrochloride | Lidocaine | L-Aspartic aicd sodium | Choline chloride | Adenine | Forskolin | Propoxur | Adiphenine hydrochloride | Ribavirin | Phenytoin sodium |
相關(guān)庫(kù) | 經(jīng)典已知活性庫(kù) | 抗癌活性化合物庫(kù) | 抗癌上市藥物庫(kù) | 已知活性化合物庫(kù) | 離子通道庫(kù) | 神經(jīng)退行性疾病化合物庫(kù) | 膜蛋白靶向化合物庫(kù) | 藥物功能重定位化合物庫(kù) | 疼痛相關(guān)化合物庫(kù) | 抗癌臨床化合物庫(kù) |
成立日期 | 2013-04-18 (12年) | 注冊(cè)資本 | 566.265100萬(wàn)人民幣 |
員工人數(shù) | 100-500人 | 年?duì)I業(yè)額 | ¥ 1億以上 |
主營(yíng)行業(yè) | 天然產(chǎn)物,生化試劑,分子生物學(xué),分子砌塊,生物技術(shù)服務(wù) | 經(jīng)營(yíng)模式 | 貿(mào)易,工廠,試劑,定制,服務(wù) |
產(chǎn)品名稱 | 價(jià)格 | 公司名稱 | 報(bào)價(jià)日期 | |
---|---|---|---|---|
詢價(jià) |
VIP7年
|
陜西締都醫(yī)藥化工有限公司
|
2024-05-08 | |
詢價(jià) |
VIP5年
|
陜西締都醫(yī)藥化工有限公司
|
2024-09-24 | |
詢價(jià) |
VIP5年
|
武漢鼎信通藥業(yè)有限公司
|
2024-11-15 | |
詢價(jià) |
VIP1年
|
寶雞締都醫(yī)藥化工有限公司
|
2024-10-15 |